US10844041B2ActiveUtilityA1

Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use

Assignee: ABBVIE OVERSEAS SARLPriority: Sep 14, 2017Filed: May 19, 2020Granted: Nov 24, 2020

Est. expirySep 14, 2037(~11.2 yrs left)· nominal 20-yr term from priority

Inventors:Robert J. Altenbach Andrew Bogdan Sylvain Couty Nicolas Desroy Gregory A. Gfesser Christopher Gaëtan Housseman Philip R. Kym Bo Liu Thi Thu Trang Mai Karine Fabienne Malagu Nuria Merayo Merayo Olivier Laurent Picolet Mathieu Rafaël Pizzonero Xenia B. Searle Steven Emiel Van Der Plas Xueqing Wang Ming C. Yeung

C07D 215/36C07D 471/04C07D 401/04A61P 11/00C07D 401/14C07D 231/56C07D 213/30C07C 311/45C07D 401/12C07D 213/71A61P 1/00C07D 213/64C07D 235/28A61P 1/18A61P 15/00A61K 31/47

PatentIndex Score

Cited by

References

Claims

Abstract

The invention discloses compounds of Formula (I), wherein A 1 , R 1 , R 2 , R 3 , R 4 , and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

Claims

exact text as granted — not AI-modified

We claim: 
     
       1. 1-{5-ethyl-2-[(propan-2-yl)oxy]pyridin-3-yl}-N-(2-methylquinoline-5-sulfonyl)cyclopropane-1-carboxamide. 
     
     
       2. 1-{5 ethyl-2-[(propan-2-yl)oxy]pyridin-3-yl}-N-(2-methylquinoline-5-sulfonyl)cyclopropane-1-carboxamide or a pharmaceutically acceptable salt thereof.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.